These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 3698544)

  • 1. In vitro activity of DJ-6783 (a keto carboxylic acid) compared with six other orally administered antimicrobial agents.
    Jones RN; Ayers LW; Barry AL; Gerlach EH; Sommers HM; Thornsberry C; Fuchs PC
    Diagn Microbiol Infect Dis; 1986 Apr; 4(4):315-26. PubMed ID: 3698544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
    McCarter YS; Mazens-Sullivan MF; Bartlett RC
    Chemotherapy; 1992; 38(5):308-18. PubMed ID: 1337507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1994). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Kitagawa R; Igari J; Oguri T; Kosakai N; Yamaguchi K; Kashitani F; Yonezu S; Yamanaka Y; Takaha M; Iori F
    Jpn J Antibiot; 1996 May; 49(5):465-93. PubMed ID: 8752862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of CI-934 compared with ciprofloxacin, enoxacin, norfloxacin, and vancomycin.
    Floyd-Reising SA; Kelley SG; Hindler JA; Young LS
    Diagn Microbiol Infect Dis; 1987 Apr; 6(4):301-6. PubMed ID: 3472704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spectrum and antimicrobial activity of alexomycin (PNU-82, 127), a peptide compound projected for use in animal health.
    Marshall SA; Jones RN
    Diagn Microbiol Infect Dis; 1999 Mar; 33(3):181-6. PubMed ID: 10092967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone.
    Gooding BB; Jones RN
    Antimicrob Agents Chemother; 1993 Feb; 37(2):349-53. PubMed ID: 8043036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enoxacin: worldwide in-vitro activity against 22451 clinical isolates.
    Siporin C; Towse G
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():47-55. PubMed ID: 6594322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of trovafloxacin (CP 99,219), a new fluoroquinolone against hospital isolates.
    Ling TK; Liu EY; Cheng AF
    Chemotherapy; 1999; 45(1):22-7. PubMed ID: 9876206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim.
    Neu HC; Labthavikul P
    Antimicrob Agents Chemother; 1982 Jul; 22(1):23-7. PubMed ID: 6214995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro activity of enoxacin against aminoglycoside-resistant gram-negative bacilli and other clinical isolates.
    Duncan IB; Skulnick M; Marshall PW
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():1-6. PubMed ID: 6438046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1993). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H
    Jpn J Antibiot; 1995 Nov; 48(11):1757-87. PubMed ID: 8558757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1992). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
    Jpn J Antibiot; 1995 Nov; 48(11):1627-57. PubMed ID: 8558754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.
    Barry AL; Jones RN
    Antimicrob Agents Chemother; 1984 Jun; 25(6):775-7. PubMed ID: 6234858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
    Guimaraes MA; Noone P
    J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1995). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Takanashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Kosakai N; Yamaguchi K; Matsumoto T; Kashitani F; Tanaka M
    Jpn J Antibiot; 1997 Mar; 50(3):219-50. PubMed ID: 9575353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM-1091) and PD131628.
    Barrett MS; Jones RN; Erwin ME; Johnson DM; Briggs BM
    Diagn Microbiol Infect Dis; 1991; 14(5):389-401. PubMed ID: 1665774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lomefloxacin, a new fluoroquinolone. Studies on in vitro antimicrobial spectrum, potency, and development of resistance.
    Aldridge KE; Henderberg A; Gebbia K; Schiro DD; Janney A; Sanders CV
    Diagn Microbiol Infect Dis; 1989; 12(3):221-33. PubMed ID: 2791485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro activity of tosufloxacin, a new quinolone antibacterial agent.
    Cooper MA; Andrews JM; Wise R
    J Antimicrob Chemother; 1992 Jun; 29(6):639-47. PubMed ID: 1506348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
    Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
    J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.